PAD PROTOKOLÜ

Kaynaklar:

1-Mai, E. K., U. Bertsch, J. Durig, et al. 2015. "Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma." Leukemia.

2- Lee, S. S., C. Suh, B. S. Kim, et al. 2010. "Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety." Ann Hematol 89(9):905-912.

3-Reeder, C. B., D. E. Reece, V. Kukreti, et al. 2010. "Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma." Blood 115(16):3416-3417.

4-Morgan, G. J., J. A. Child, W. M. Gregory, et al. 2011. "Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial." Lancet Oncol 12(8):743-752.

5-Palumbo, A., F. Gay, S. Bringhen, et al. 2008. "Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma." Ann Oncol 19(6):1160-1165.

6-Sonneveld P, Schmidt-Wolf IG, van der Holt B et al. 2012 "Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial". J Clin Oncol. 30(24):2946-55.